Reducing treatment burden in the era of CFTR modulators
- PMID: 37321239
- DOI: 10.1016/S2213-2600(23)00223-0
Reducing treatment burden in the era of CFTR modulators
Conflict of interest statement
PDR's institutions have received reimbursement for services provided as part of a central over-reading centre network for multiple breath washout in both investigator and pharmaceutical sponsored studies (including Vertex Pharmaceuticals). TAD's institution has received payment on a per-patient basis derived from pharmaceutical studies, honoraria for symposia, and educational meetings from Vertex Pharmaceuticals. CEW's institution has received payment for consultancy work on a per-patient basis derived from pharmaceutical studies sponsored by GSK, Boehringer Ingelheim, and Vertex Pharmaceuticals; a research grant from Novo Nordisk; honoraria for participation in advisory boards, symposia, and meetings from DKBmed, Novartis Pharmaceuticals, University of Miami, and Vertex Pharmaceuticals; travel support from Vertex Pharmaceuticals; and serves on the International Advisory Board for Vertex Pharmaceuticals.
Comment in
-
Reducing treatment burden in the era of CFTR modulators - Authors' reply.Lancet Respir Med. 2023 Sep;11(9):e79. doi: 10.1016/S2213-2600(23)00224-2. Epub 2023 Jun 12. Lancet Respir Med. 2023. PMID: 37321238 No abstract available.
Comment on
-
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. Lancet Respir Med. 2023. PMID: 36343646 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
